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Raritan, NJA B S T R A C TBackground: Biopharmaceutical companies face multiple external
pressures. Shareholders demand a proﬁtable company while govern-
ments, nongovernmental third parties, and the public at large expect
a commitment to improving health in developed and, in particular,
emerging economies. Current industry commercial models are inad-
equate for assessing opportunities in emerging economies where
disease and market data are highly limited. Objective: The purpose
of this article was to deﬁne a conceptual framework and build an
analytic decision-making tool to assess and enhance a company’s
global portfolio while balancing its business needs with broader social
expectations. Methods: Through a case-study methodology, we
explore the relationship between business and social parameters
associated with pharmaceutical innovation in three distinct diseaseee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.07.005
sm.nl., edith.maes@telenet.be.
ndence to: Edith Maes, Maastricht School of Manageareas. The global burden of disease–based theoretical framework
using disability-adjusted life-years provides an overview of the burden
associated with particular diseases. The social return on investment is
expressed as disability-adjusted life-years averted as a result of the
particular pharmaceutical innovation. Simultaneously, the business
return on investment captures the research and development costs
and projects revenues in terms of a proﬁtability index. Conclusions:
The proposed framework can assist companies as they strive to meet
the medical needs of populations around the world for decades to come.
Keywords: burden of disease, pharmaceuticals, portfolio management.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Medicines prevent and treat diseases, enabling people to live
longer, healthier, and more productive lives, and consequently
contribute signiﬁcantly to social and economic advances. Research-
based biopharmaceutical companies remain the prime innovators
of drugs, vaccines, and diagnostics to help countries and regions
improve the health of both their people and their economies.
Companies recognize that market demand and market need
are not the same thing. In a 2004 study, Acemoglu and Linn [1]
reported a direct link between a market’s size and the level of
innovation within the biopharmaceutical industry’s products in
that market. A perfect example of this connection is neglected
tropical diseases. There is an unmet need within developing
markets for medical solutions to neglected tropical diseases but
little demand for these products due to patients’ inability to pay.
Nevertheless, companies recognize the need to address these
challenges in a way that reconciles ﬁnancial return with corpo-
rate social responsibility.
Today’s biopharmaceutical companies strive to maintain a
balanced portfolio of products that beneﬁt society with those thatbeneﬁt business. Strategic sustained investments in research and
development (R&D) are critical to ensuring this balance, but
limited market data for emerging markets can limit a company’s
ability to assess opportunities across the globe. Current indices
used to gauge performance in business and societal measures—
speciﬁcally the Access to Medicines Index (ATMI) [2] and the
Productive Innovation Index [3]—operate in silos.
The ATMI measures the pharmaceutical industry’s progress in
better enabling access to medicines. The ATMI uses a weighted
analytical framework to consistently capture and compare com-
pany data across seven technical areas of focus, namely, general
access to medicine management, public policy and market
inﬂuence, R&D, pricing manufacturing and distribution, patents
and licensing, capability advancement, and product donations.
Within each area, the index assesses four aspects of company
action: commitment, transparency, performance, and innova-
tion. The ATMI focuses on products targeting high-burden dis-
eases but does not include data on the impact each product has
had, or may have, on the burden of disease itself.
The Productive Innovation Index measures and scores the
companies’ ability to deliver innovation to market, by objectivelyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ment, Endepolsdomein 150, 6229 EP Maastricht, The Netherlands.
Table 1 – SRI model parameters deﬁned measure.
Variable Deﬁnition Source/calculation
DW Disability weight of the
relevant disease
GBD 2010 [5]
NInc Annual incidence/
prevalence of the relevant
disease
GBD 2010 [5];
published
literature
PMortality Intervention effect on
disease mortality (%)
Assumption derived
from published
literature
PMorbidity Intervention effect on
disease morbidity (%)
Assumption derived
from published
literature
DALYA DALYs of the base-case
scenario (no intervention)
DALYA ¼ YLDA þ
YLLA; GBD 2010 [5]
YLDA YLD of the base-case
scenario (no intervention)
YLLA YLL of the base-case
scenario (no intervention)
DALYB DALY of the base-case DALYB ¼ YLDB þ
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 3 2 – 7 3 8 733measuring their performances in successfully commercializing,
not necessarily discovering, new molecules. The index is based
on publicly available data and ranks innovation in terms of such
factors as the speed with which a product is brought to market
and whether it achieved reimbursement. This index does not
incorporate societal value factors.
The purpose of this study was to identify a new conceptual
framework that combines measurements of societal value with
those of business returns. This approach of evaluating the
combined returns on investment has not been investigated yet.
The proposed framework provides a novel way of deﬁning the
overall impact of a company’s product portfolio. The advantages
of net present value (NPV) and capital budgeting are covered in
the business management literature, and the societal impact
measured in disability-adjusted life-years (DALY) is covered in
epidemiology and health policy literature. Although the study
builds on these respective insights, the joint framework develops
a new business lens through which companies can better
optimize their portfolio. It also provides better insight into
potential R&D investments and helps identify opportunities to
partner on innovative products targeting neglected diseases and
other emerging market needs.scenario (with
intervention)
YLLB þ RF
YLDB YLD of the base-case
scenario (with
intervention)
YLDB ¼ YLDA 
(1 Pmorbidity)
YLLB YLL of the base-case
scenario (with
intervention)
YLLB ¼ YLLA 
(1  Pmortality)
RF RF; YLD due to extending
life
RF ¼ YLLA  Pmortality
 DW  (1 
Pmorbidity)
ΔDALY Change in DALY count from
the base-case scenario to
a scenario with an
additional intervention
ΔDALY ¼ DALYA 
DALYB
DALY, disability-adjusted life-year; GBD, Global Burden of Disease;
RF, residual factor; SRI, social return on investment; YLD, years of
life lived with disability; YLL, years of life lost.Methods
The development of this framework requires identifying separate
measures for the societal return on investment (SRI) and the
business return on investment (BRI) before overlaying these
concepts to identify commercial opportunities and areas for
R&D investment.
SRI (DALY Averted)
Prior to C.J.L. Murray and A.D. Lopez’s 1997 Global Burden of
Disease (GBD) Study in The Lancet [4], there was no way to
determine leading causes of death and disability across all
medical and public health concerns. Murray and Lopez developed
the DALY to address that gap. As a result of the DALY measure,
the researchers were able to determine the leading causes of
death and disability across all health categories. To ensure
consistent comparisons across therapeutic areas and geogra-
phies, our model utilizes DALYs averted to measure the impact
of the intervention on disease burden. This is referred to as
the SRI.
Data from the World Health Organization’s 2010 GBD project
were utilized as the basis of all societal return calculations [5].
Key GBD calculations incorporated were years of life lost (YLL),
years of life lived with disability (YLD), residual factor, DALY, and
disease-speciﬁc information (prevalence/incidence). An in-depth
explanation of the methodology in calculating these estimates
has been published elsewhere [4,6,7]. Table 1 provides all param-
eters with their respective deﬁnitions while Figure 1 provides a
graphical representation of the impact of the intervention on
disease mortality (ΔYLL) and morbidity (ΔYLD), collectively
deﬁned as DALY averted.
DALY (and YLL and YLD) and prevalence/incidence estimates
from the WHO GBD publication were utilized for each disease
state speciﬁc to geographical regions. Using these baseline (with-
out novel intervention or DALY A) DALYs and prevalence for each
disease, we calculated base DALY/patient, YLL/patient (p-mortal-
ity), and YLD/patient (p-morbidity) for the speciﬁc disease. The
total DALYs averted (ΔDALY) are obtained by subtracting scenario
B from scenario A, where scenario A represents the base-case
scenario without the intervention and scenario B represents the
remaining DALYs taking into account the effect of the interven-
tion in reducing the disease burden. A two-step approach wasthen used to calculate the potential treatment population and
potential DALYs averted. First, for each calculated yearly preva-
lence/incidence estimate, a factor was applied to identify diag-
nosed patients. Second, an additional factor was applied to
account for potential market share (peak share provided in the
table) of the diagnosed patient population for the intervention.
Assumptions were used to estimate the interventional effect on
YLD and YLL of the patient population treated (p-morbidity and
p-mortality, respectively). These estimates were applied to the
annual DALY estimates for each year modeled to calculate the
number of annual DALYs averted.BRI (Proﬁtability Index)
Methods for calculating R&D costs for and potential earnings
from pharmaceutical products are well established. These fore-
casting methods are published in detail elsewhere [8,9]. All
biopharmaceutical companies must consider whether the poten-
tial proﬁts of a product will offset the costs of R&D. Further
complicating this evaluation is the knowledge that most products
will fail at some point during the R&D process, leading to addi-
tional costs that must be recouped during the marketing of other,
successful, products.
To develop performance measures, a proﬁtability index is ﬁrst
established. The proﬁtability index is the estimated NPV
Fig. 1 – Impact of the intervention on disease mortality and morbidity. DALY, disability-adjusted life-year; DW, disability
weight; YLDA, years of life lived with disability of the base-case scenario (no intervention); YLDB, years of life lived with
disability of the base-case scenario (with intervention); YLLA, years of life lived of the base-case scenario (no intervention);
YLLB, years of life lived of the base-case scenario (with intervention).
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development. Recent calculations have estimated the average
cost of development to be $1.8 billion [8]. Clearly, there is a wide
variation because costs and the probability of successfully bring-
ing a product to market differ between therapeutic areas. The
methodology as presented by Paul et al. [8] and that we adopted
takes these variances into account. The authors advocate an
eight-step process for estimating the risk-adjusted costs incurred
for any compound traveling along the discovery, development,
and registration process [8]. They calculated the risk-adjusted
cost through a stage-gate process and based their results on a
broad sample of industry projects. This adds up to a total average
product cost. We use this ﬁgure as default knowing that each of
the assumptions of the process can be modiﬁed and cost
estimates adjusted according to the speciﬁc compound being
examined. In practice, each company will ask a team of internal
experts to estimate these cost and attrition rates. Although our
model could simulate the outcome for any speciﬁc compound at
each stage, we do not possess the raw data because these must
be generated prospectively, not retrospectively.
The NPV is calculated as the present value of the sum of cash
ﬂows obtained during the commercial phase (i.e., sales revenues
minus the costs of marketing and of goods produced for each
year of the sales forecast) minus the present value of the ﬁxed
cost of initial investment in R&D (which is accrued as a lump sum
at the time of launch) [10].
NPV ¼ CF0 þ ∑
T
i¼1
CFT
ð1 þ rÞi
NPV ¼ CF0 þ CF1ð1 þ rÞ1 þ
CF2
ð1 þ rÞ2 þ . . . þ
CFT
ð1 þ rÞT
where CF0 is the sum of the initial investment costs before
launch. These initial investments include the scientiﬁc-
technical product development costs amassed throughout the
early and late stages of development and are adjusted for risk
and probability of success (or failure). This is a negative number
because these are expenditures, not proﬁts.
The latter half of the equation,∑Ti¼1
CFT
ð1þ rÞi, is the sum of all future
cash ﬂows generated commercially after launch. As default, we are
using a sales forecast period of 20 years and a ﬁxed percentage ofsales to represent the cost of goods (COG) and of sales and market-
ing (e.g., COG: 10% and sales and marketing: 30%). These default
values can be modiﬁed to represent product-speciﬁc costs that may
be incurred. The effect of patent loss for the original product after
approximately 10 to 13 years of sales has been taken into account in
the commercial forecast in terms of both diminished market share
and price competition from generics. Nonetheless, it would be better
if a longer period of time is taken into account, provided such data
are available. Furthermore, the COG is likely to vary over time. We
maintain the 10% ratio of COG over sales because there will be
economies of scale generated over time that lower the production
cost. The effect of lower prices, especially when generics are
introduced, is balanced by the economies of scale and of learning
derived from years of manufacturing and marketing a product.
Within that equation, r represents the cost of capital. The
weighted average cost of capital is the rate that a company is
expected to pay on average to all its security holders to ﬁnance its
assets. Companies usually use the weighted average cost of capital
to see whether the investment projects available to them are
worthwhile to undertake. We have used default values derived
from literature concerning capital budgeting in the pharmaceut-
icals industry, which is 11% prelaunch [11,12] and 8% postlaunch
[13]. Values can be changed according to a ﬁrm’s capital budgeting
rules. They should, however, be the same for all products.
Finally, we arrive at the Proﬁtability Index (PI), which is expressed
as a ratio. The numerator is composed of the present value of all
sales cash ﬂows subsequent to launching the product. This is
divided by the cost of the initial investment (i.e., the denominator).
Thus, instead of subtracting the initial investment from future sales
revenues, the key variables are divided. The outcome obtained is a
ratio proven in literature to be more relevant [10].
PI ¼ PV
Co
Results
We selected three disease states as case studies to demonstrate the
concept. When calculating both the SRI and the BRI, assumptions
regarding market share uptake, pricing, and product proﬁle for the
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 3 2 – 7 3 8 735intervention were used. These assumptions were based on generally
accepted treatment/policy guidelines and recent product launches.
Case Study 1: Malaria (Falciparum)
Malaria is a disease associated with high mortality, especially in
children and young adults in the world’s poorest countries. Pre-
venting the disease with a vaccine could have a signiﬁcant impact
on YLL and YLD; however, access and affordability are key barriers
for the development of such products. For “neglected” diseases such
as malaria, which are mostly infectious diseases prevalent in the
world’s poorest countries, most individuals and governments are
unable to pay for them, limiting the interest of private-sector R&D
investments without additional funding sources.
Proposed intervention: Vaccine
We used our model to determine the social and business returns
from hypothetical ﬁrst- and second-generation vaccines. A ﬁrst-
generation vaccine would reduce disease burden by approximately
8 million DALYs, whereas an improved second-generation malaria
vaccine would have a signiﬁcantly larger public health impact on
the burden of disease with nearly 12 million DALYs averted
(Table 2). This reduction in disease burden is a result of malaria
cases and associated mortality prevented in this population.
With either intervention, however, the PI will be below 1 based
on revenue forecasts over 20 years. At prices of $5 and $7 per dose
for the ﬁrst- and second-generation vaccine, respectively, the
manufacturer will not be able to recoup investment costs (Table 2).
Case Study 2: Hepatitis C Virus
Before the availability of donor blood screening in 1992, hepatitis
C virus (HCV) infection was primarily spread through blood
transfusions. Given the asymptomatic nature of the disease and
a general misunderstanding of the risk factors, nearly 70% ofTable 2 – Case study SRI and BRI results.
Scenario Total patients/
cohort
Tot
treate
in
Malaria
Scenario 1: First-generation vaccine
in sub-Saharan Africa with 52%
p-morbidity and 52% p-mortality
35,000,000 2
Scenario 2: Second-generation
vaccine with 85% p-morbidity and
85% p-mortality
35,000,000 2
Hepatitis C
Scenario 1: Treatment in G7
countries with 80% p-morbidity
and 80% p-mortality
8,361,908
Scenario 2: Implement Test & Treat
G7 countries
8,361,908
Scenario 3: Implement Test & Treat
worldwide
18,921,908
Diabetes
Scenario 1: Treatment in G7
countries with 80% p-morbidity
and 80% p-mortality
75,000,000
Scenario 2: Increase access to
treatment worldwide
375,000,000 1
BRI, business return on investment; DALY, disability-adjusted life-year; G
on investment.
* Cost per treatment assumptions based on low-/medium-/high-incomecases remain undiagnosed even in developed markets and less
than 50% of diagnosed patients are treated. Until recently, the
standard of care (peg interferon þ ribavirin) was effective in less
than 50% of patients with genotypes 1 and 4, which together
account for nearly 70% of diagnosed cases. To address this deadly
disease, a combination of detection and treatment methods is
critical. Although rates of the disease are declining, morbidity
and mortality associated with late-stage liver disease, speciﬁcally
cirrhosis and cancer, are high, resulting in high DALYs globally.
Proposed intervention: Hepatitis C detection and treatment
In a base-case simulation restricted to high-income G7 countries
(North America, Western Europe, and Japan), we proposed a more
effective add-on treatment in addition to the existing standard of
care for patients diagnosed with HCV genotype 1 or 4. Its impact
would result in a marginal reduction in disease burden as
accounted by DALYs averted because so few patients are cur-
rently diagnosed and treated. In the subsequent scenario, a
higher uptake could be obtained through a “Test & Treat”
program (as recommended, for instance, by the US Centers for
Disease Control and Prevention) [14]. As depicted, Test & Treat
within high-income markets provides incremental DALY aver-
sion because more patients are receiving treatment. Finally, the
last scenario imagines a Test & Treat program in low- and
middle-income countries, where two thirds of the disease burden
lies (Table 2).
The PI in the base case is high because the product is
launched in developed markets. The PI remains high under the
Test & Treat scenario and in a tiered pricing approach in
emerging markets (Table 2).
Case Study 3: Type 2 Diabetes
Noncommunicable diseases, such as diabetes, are becoming
increasingly prevalent primarily because of lifestyle changes inal patients
d/vaccinated
peak year
Total
DALYs
DALYs
averted
Cost per
treatment
per year ($)
PI
2,750,000 22,613,649 7,560,007 15 0.83
2,750,000 22,613,649 12,301,539 21 0.81
284,447 2,054,688 53,125 4370 3.2
522,881 2,054,688 97,656 4370 4.9
1,183,211 12,111,413 575,676 Tiered* 6.2
2,446,875 6,814,654 709,630 1200 5.6
2,234,375 46,823,256 3,480,403 Tiered* 6.3
DP, gross domestic product; PI, Proﬁtability Index; SRI, social return
countries, based on GDP.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 3 2 – 7 3 8736both developed and emerging markets. The latter countries are in
a particularly difﬁcult situation because they are often still facing
infectious diseases no longer seen in the developed world while
battling the same chronic conditions.
The number of people with diabetes is increasing because of
several factors, including population growth, aging, urbanization,
and last but not least the increasing prevalence of obesity and
physical inactivity. According to the International Diabetes Fed-
eration, 371 million people worldwide are living with diabetes.
Approximately 25.8 million people—about 8.3% of the population
—have diabetes in the United States, where the disease is
estimated to be the seventh leading cause of death. The World
Health Organization projects that diabetes will be the seventh
leading cause of death worldwide by 2030.
In most people at risk for type 2 diabetes, obesity causes the
body to resist the action of insulin, and if the pancreatic beta cell
cannot produce enough insulin, hyperglycemia and type 2 dia-
betes results. If left uncontrolled, type 2 diabetes can lead to
serious complications, although improved glycemic control has
been demonstrated to reduce the onset and progression of these
complications.
Proposed intervention: Novel type 2 diabetes treatment
In contrast to malaria and HCV infection in which about 90% of
the burden is attributed to YLL, the burden caused by diabetes is
almost equally split between YLL and loss in quality of life. In a
base-case simulation restricted to high-income countries, a new
treatment (assuming it is similar to a product such as canagli-
ﬂozin) with improved effectiveness paired with a marginal
increase in market share could avert approximately 1 million
DALYs. Expanding distribution from high-income countries to
the entire world could signiﬁcantly increase the number of
averted DALYs (Table 2) as more patients are exposed to the
novel treatment with higher efﬁcacy and better tolerability.
The proﬁtability for both scenarios is relatively high even with
a tiered pricing approach in emerging markets. This high level of
proﬁtability is attributed to the chronic nature of the disease, and
thus the continuing need for treatment, and even more impor-
tantly the high prevalence of type 2 disease in high-income
markets.Fig. 2 – Strategic mapping of portfolio.Developing modeled products into a portfolio
No pharmaceutical company develops a product in a vacuum but
rather develops a well-balanced portfolio addressing GBD and
business needs. In Figure 2, we have mapped each case study
onto a grid to visualize the potential product’s impact on both the
disease burden and the PI. By mapping the products together, it
offers a commercial lens for how multiple products, some with
higher BRI and some with higher SRI, may complement each
other in a balanced portfolio.
Our ﬁndings also indicate that companies do not have to
consider portfolio products in silos. Products that have a good BRI
in high-income markets can be either marginally proﬁtable or no
cost in emerging markets. This framework enables companies to
better calculate what, if any, expenditures, tiered prices, or
partnerships would be needed to market a single product across
all countries, regardless of income levels.Discussion
The GBD-based theoretical framework outlined above overlays
for the ﬁrst time the social return of a product over the business
return. The dual framework serves populations globally and
consequently improves a ﬁrm’s performance in terms of corpo-
rate social responsibility. The amount of investment and support
that is needed can now be computed, enabling ﬁrms to assess
how many of such programs can be undertaken and sustained
within their portfolio. This does not, of course, preclude corporate
philanthropy programs.
The proposed method also better reﬂects the societal impact
when expressed in DALYs compared with the number of lives
saved. In the past, developing countries were primarily affected
by premature death; today, quality of life is an important factor
as disease patterns are shifting and therapy moving from acute
to chronic. Hence, it is important to consider the two aspects
that make up the DALY metric: (1) YLL and (2) YLD. More
research is needed to compare DALYs and QALYs, however. In
particular, the conversion between these two metrics warrants
further investigation.DALY, disability-adjusted life-year.
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the GBD 2010 database are in line with previous analyses based
on literature research. The GBD 2010 database is by far preferred
because it represents the world’s most extensive and objective
database of diseases in the world. Having worked under various
circumstances with this new analytic tool, we are convinced that
it can be used to assess the product positions for virtually all the
illnesses reported in the GBD database.
Using the DALY metric as the primary indicator adequately
summarizes the burden of premature mortality and disability.
The method allows comparing illnesses with high morbidity
versus those with high mortality. More research is needed
to compare DALYs and QALYs, however. In particular, the
conversion between these two metrics warrants further
investigation.
As stated, our objective in developing this model was not to
evaluate products in a vacuum, but rather as part of a complete
portfolio, balancing the needs of business with those of society.
Pharmaceutical companies should not feel compelled to score
high in all disease areas and on all the indexes proposed. Rather,
a trade-off should be pursued between diseases with high SRI and
low BRI, and vice versa. Given the varying nature of disease
burden patterns across nations and population groups, compa-
nies focusing on modern, lifestyle diseases as well as poverty-
related diseases are in a position to score high in both the social
and business rankings. Our case studies revealed some unique
funding and partnership opportunities in order to maintain that
balance.
External Funding Commitments
As we learned from Acemoglu and Linn, there is a direct causal
link between expected market size and product innovation in the
biopharmaceutical industry. In the case of diseases such as
malaria, a traditional development program would therefore be
unlikely according to its expected proﬁtability. There is an
increasing interest, however, on the part of both industry and
governments to develop public-private partnerships to discover
and support innovative products to combat neglected diseases.
These partnerships include “push” mechanisms that subsidize
research and “pull” mechanisms such as advance market com-
mitments that reward R&D programs.
Importance of Public Health Programs
Public health programs are often critical in raising the awareness
of a disease that the public may not view as a threat and
therefore may not seek treatment for. This is demonstrated best
in the case of HCV infection, for which developing a proﬁtable
new treatment hinges on the successful implementation of
public health programs that would increase the awareness and
diagnosis of the disease. Treatments for chronic HCV infection
are evolving at such a rapid pace that in 5 years, interferon-free,
oral, direct-acting antiviral regimens may achieve close to 90%
cure rates across viral genotypes and regardless of IL-28B allele
status. What is currently lacking in this optimistic perspective is
a national “ﬁnd-and-treat” policy aimed at achieving maximum
identiﬁcation of HCV carriers and providing new-generation
therapies to a large proportion of those identiﬁed cases. The US
Centers for Disease Control and Prevention program of screening
“baby boomers” is an example of a targeted, mass-screen-
ing program that may deliver good results when used in combi-
nation with more effective early treatment and the prevention
of disease progression to symptomatic cases. The individual
and societal beneﬁts of such a strategy would be substantial
and the costs are in step with other well-established public
health measures [14].Healthy Investment in High BRI Products
Without a healthy investment in high-BRI products, invest-
ment in high-SRI products is impossible. The diabetes case
study highlights the proﬁtability of a chronic treatment (that is
not curative) of a disease that primarily affects the industrial-
ized high-income markets. There is a considerable increase in
the product impact on GBD when expanding access from G7 to
worldwide. This geographic expansion allows increasing the
overall access to medicines while moderately increasing proﬁt-
ability (provided a company is committed to using equitable,
differential pricing [15]). Proﬁts from industrialized market
products can also sustain investment in R&D for products with
high SRIs.
The decision framework provides a dynamic view on how the
results obtained on BRI and SRI can be improved or optimized. A
current limitation of the framework is the dependence of
assumptions concerning the effectiveness of the proposed med-
ical intervention. Further research should be conducted to
develop a methodology for determining proper medical interven-
tion assumptions based on real-world data.Conclusions
The proposed framework and case study applications illus-
trate the necessary balance between addressing high disease
burden across various countries and populations and main-
taining a reasonable, risk-adjusted return on investment to
sustain pharmaceutical research, development, and produc-
tion costs. Ultimately, this framework can assist innovation-
driven biopharmaceutical companies as they strive to meet
the medical needs of patients around the world for decades
to come.
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